Jin-Hyeok Hwang

Dr. Jin-Hyeok Hwang


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SASoomin Ahn
Soomin Ahn
JLJong-Chan Lee
Jong-Chan Lee
DSDong Woo Shin
Dong Woo Shin
JKJaihwan Kim
Jaihwan Kim
JHJin-Hyeok Hwang
Jin-Hyeok Hwang
Pembrolizumab appears promising for patients with programmed cell death ligand-1 (PD-L1)-positive solid tumors. However, data on immunotherapy for biliary tract cancers (BTC) are limited. We aimed to investigate the predictive value of PD-L1 expression as an immunotherapeutic biomarker in BTC. Patients with advanced BTC (n = 175) were screened for PD-L1 expression using PharmDx assay and microsatellite instability (MSI) status. Of the total of 175 patients, 125 (71%) showed tumoral PD-L1 positivity (≥ 1%) while only two (2/142, 1.4%) showed MSI-High. Among 175 patients, 26 patients were treated with pembrolizumab as a second-line therapy, and tumor response was evaluated. Separating these patients into two groups by PD-L1 expression (high [≥ 50%] vs. low [< 50%]), overall response rate was 23% (56% [5/9] in high PD-L1 group vs. 6% [1/17] in low PD-L1 group, P = 0.004). Disease control rate was also higher in high PD-L1 group (78% vs. 35%, P = 0.019). The six responders showed median progression-free survival of 5.8 months after starting pembrolizumab, and none of them was MSI-High. High PD-L1 expression was associated with a better response to pembrolizumab. PD-L1 expression can potentially serve as an alternative predictive biomarker for pembrolizumab therapy in advanced BTC.

18 October 2012 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
EJEun Sun Jang
Eun Sun Jang
SJSook-Hyang Jeong
Sook-Hyang Jeong
SHSung Ho Hwang
Sung Ho Hwang
HKhyunyoung kim
hyunyoung kim
SASoyeon Ahn
Soyeon Ahn
DLDong Ho Lee
Dong Ho Lee
Background: Liver function tests (LFTs) can be affected by many factors and the proposed effects of coffee on LFT require a comprehensive evaluation. The aim of this study was to elucidate whether drinking coffee, smoking, or drinking alcohol have independent effects on LFTs in Korean health-check examinees. Methods: We used the responses of 500 health-check examinees, who had participated in a self-administered questionnaire survey about coffee, alcohol drinking, and smoking habits. Results: Coffee consumption was closely related to male gender, high body mass index (BMI), alcohol drinking, and smoking. On univariable and multivariable analyses, drinking coffee lowered serum levels of total protein, albumin, and aspartate aminotransferases (AST). On multivariable analyses, smoking raised serum γ-glutamyl transferase (GGT) level and decreased serum protein and albumin levels, while alcohol drinking raised GGT level after adjustment for age, gender, regular medication, BMI, coffee and alcohol drinking amounts, and smoking. Conclusions: Coffee consumption, smoking, and alcohol drinking affect the individual components of LFT in different ways, and the above 3 habits each have an impact on LFTs. Therefore, their effects on LFTs should be carefully interpreted, and further study on the mechanism of the effects is warranted.

1 December 2015 in Medicine
Verified
Journal Article
Open access
YLYoonsuk Lee
Yoonsuk Lee
HKHaeryoung Kim
Haeryoung Kim
HKHyoung Woo Kim
Hyoung Woo Kim
JLJong-Chan Lee
Jong-Chan Lee
KPKyu-Hyun Paik
Kyu-Hyun Paik
JHJin-Hyeok Hwang
Jin-Hyeok Hwang
There is limited data on miRNA expression in pancreatic neuroendocrine tumors (PanNETs). In this study, we aimed to identify miRNAs that could be potential prognostic biomarkers of PanNETs in patients who underwent curative surgery. For miRNA target screening, 2 primary PanNETs and corresponding liver metastases were screened for miRNA expression by the NanoString nCounter analysis. Candidate miRNAs were selected by ≥2-fold difference of expression between metastatic versus primary tumor. For miRNA target validation, quantitative real-time PCR was performed for candidate miRNAs on 37 PanNETs and matched nonneoplastic pancreata, and the miRNA levels were correlated with the clinicopathological features and patient survival data. Eight miRNAs (miRNA-27b, -122, -142–5p, -196a, -223, -590–5p, -630, and -944) were selected as candidate miRNAs. Only miR-196a level was significantly associated with stage, and mitotic count. When PanNETs were stratified into high (n = 10) and low (n = 27) miRNA-196a expression groups, miRNA-196a-high PanNETs were significantly associated with advanced pathologic T stage (50.0% vs 7.4%), N stage (50.0% vs 3.7%), higher mitotic counts (60.0% vs 3.7%), and higher Ki-67-labeling indices (60.0% vs 22.2%). In addition, high miRNA-196a expression was significantly associated with decreased overall survival (P = 0.046) and disease-free survival (P < 0.001) during a median follow-up of 37.9 months with the hazard ratio for recurrence of 16.267 (95% confidence interval = 1.732–153.789; P = 0.015). MiRNA-196a level may be a promising prognostic marker of recurrence in resected PanNETs, although further experimental investigation would be required.

1 January 2014 in World Journal of Gastrointestinal Endoscopy
Verified
Journal Article
Open access
WPWoo Hyun Paik
Woo Hyun Paik
NLNerenthran Loganathan
Nerenthran Loganathan
JHJin-Hyeok Hwang
Jin-Hyeok Hwang
Preoperative biliary drainage in hilar cholangiocarcinoma: When and how?

30 October 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YLYoonsuk Lee
Yoonsuk Lee
JLJong-Chan Lee
Jong-Chan Lee
SYSe Yeol Yang
Se Yeol Yang
JKJaihwan Kim
Jaihwan Kim
JHJin-Hyeok Hwang
Jin-Hyeok Hwang
The effectiveness of neoadjuvant therapy (NAT) remains unclear in resectable pancreatic cancer (PC) as compared with upfront surgery (US). The aim of this study was to investigate the survival gain of NAT over US in resectable PC. PubMed and EMBASE were searched for studies comparing survival outcomes between NAT and US for resectable PC until June 2018. Overall survival (OS) was analyzed according to treatment strategy (NAT versus US) and analytic methods (intention-to-treat analysis (ITT) and per-protocol analysis (PP)). In 14 studies, 2,699 and 6,992 patients were treated with NAT and US, respectively. Although PP analysis showed the survival gain of NAT (HR 0.72, 95% CI 0.68–0.76), ITT analysis did not show the statistical significance (HR 0.96, 95% CI 0.82–1.12). However, NAT completed with subsequent surgery showed better survival over US completed with adjuvant therapy (HR 0.82, 95% CI 0.71–0.93). In conclusion, the supporting evidence for NAT in resectable PC was insufficient because the benefit was not demonstrated in ITT analysis. However, among the patients who completed both surgery and chemotherapy, NAT showed survival benefit over adjuvant therapy. Therefore, NAT could have a role of triaging the patients for surgery even in resectable PC.

1 May 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
JLJong-Chan Lee
Jong-Chan Lee
JKJin Won Kim
Jin Won Kim
SASoyeon Ahn
Soyeon Ahn
HKHyoung Woo Kim
Hyoung Woo Kim
JLJongchan Lee
Jongchan Lee
JHJin-Hyeok Hwang
Jin-Hyeok Hwang